Abstract
Rationale for Review
The health outcomes of type 1 diabetes in children are well documented, but the wider psychosocial impacts are less established and there is a lack of understanding of the effects on educational experience. These wider impacts are not only important in themselves, but also have the potential to have an effect on later life health outcomes through mechanisms such as employment, income and social status. Many patients and their families express concerns about the potential negative impact that T1DM may have on a child's attainment at school. Hypoglycaemia, hyperglycaemia and diabetic ketoacidosis as well as psychological challenges and reduced attendance due to illness and hospital appointments are all factors which may theoretically result in poorer educational attainment for children with type 1 diabetes compared with their non-diabetic counterparts.(7-9) However, there is conflicting evidence as to the exact effect T1DM has on educational attainment and the real magnitude of this impact. (10) Currently laws relating to managing children with chronic disease in school in the UK vary depending on specific country. In England, the Children and Families Act 2014 was introduced in September 2014 and imposed a statutory duty of schools to support children with medical conditions. The aim
Strengths & Limitations of this study
• This systematic review will comprehensively evaluate available peer-reviewed and grey literature reporting the impact of type 1 diabetes on educational achievement in individuals undertaking high stakes standardised testing under age 18 at the end of compulsory schooling.
• Our findings will be reported using the recommended methods and checklist of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
• Study selection and data extraction will be performed independently by two reviewers, with any disagreements resolved via a third reviewer.
• A potential limitation of this review may be varying quality and high heterogeneity amongst available studies.
F o r p e e r r e v i e w o n l y of this was to ensure schools make additional arrangements for supporting these children, relating to both physical and mental wellbeing, allowing them to achieve their academic potential. (11) As implied both in theory and in law, type 1 diabetes has the potential to significantly impact on children's school attainment. Therefore, assessing and analysing the current evidence to quantify this effect may be useful in assessing what and how much support and educational interventions should be focused on children with type 1 diabetes in school.
Objectives
The primary objective of this review is to assess and analyse the current literature available on whether type 1 diabetes has an impact on educational achievement in individuals undertaking high stakes standardised testing under 18 years of age at the end of compulsory schooling. The secondary objectives include assessing the effect of type 1 diabetes on school attendance and educational attainment at other stages on the educational trajectory if reported.
Methods
We have used the Cochrane Handbook for Systematic Reviews of Interventions (12) to structure our methodological approach and we will report our findings using the recommended methods and checklist of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). (13) This protocol was created using the Preferred Reporting Items for Systematic Review and MetaAnalysis Protocols (PRISMA-P) guidelines.(14)
Eligibility criteria
The following criteria will be used to consider inclusion and exclusion of studies for this review.
Type of study:
We will include observational studies including prospective and retrospective cohort and case control studies (and randomised controlled trials if available). We will exclude case series, case reports and expert opinion/narrative reviews.
Population:
We will include studies including individuals who have undertaken high stakes testing at the end of compulsory schooling when under 18 years of age. Intervention/Exposure: Known diagnosis of type 1 diabetes before undertaking high stakes testing at the end of compulsory schooling.
Controls/Comparators:
No diagnosis of type 1 diabetes before undertaking high stakes testing at the end of compulsory schooling.
Outcome measures:
The primary outcome will be grades obtained at the end of compulsory schooling i. 
Setting:
Included studies will be secondary school based. Studies including outcomes from educational tests undertaken in clinical or other non-school settings will be excluded.
Search methods for identification of studies
We will search the following databases from 2004 to present, and will consider only studies published using the English language.
• Comprehensive electronic literature search strategies will be used for each database. See Appendix 1 for the Ovid MEDLINE and EMBASE search strategy.
To identify additional papers, information on studies in progress, unpublished research or research reported in the grey literature will be identified through searching a range of relevant websites, including Diabetes.org.uk, and trial registers including Clinical Trials.gov. We will search Electronic Table of Contents (eTOC) of key journals for relevant studies that have been published within the last two years. We also plan to check review articles, reference lists and carry out citation tracking of included studies for any significant studies missed during the database search.
Selection of studies
To select studies for further assessment, they will be imported and organised into Eppi-Reviewer 4.0(16) and duplicates will be removed. Two independent reviewers (NO & RF) will screen the titles and abstracts of every record retrieved from the searches using the predetermined inclusion criteria using Eppi-Reviewer 4.0.(16) Records identified as potentially eligible on the basis of title and abstract will then be screened on full text according to set inclusion criteria. If there is any doubt or disagreement regarding study selection, there will be further discussion and, if required, involvement of a third reviewer (JG) to reach a consensus. Rationale for exclusion of studies at this stage will be documented. The remaining included studies will then undergo data extraction using a standardised pro-forma. A PRISMA flow diagram will be used to demonstrate the number of included and excluded studies.
Data collection
All included studies will undergo data extraction by 2 independent reviewers (NO & RF), using a standardised pro-forma. The pro-forma will be pilot tested initially to ensure consistency. Data extracted from each study will include: -Details of study e.g. first author, date of publication, country/region where study undertaken. -Details of study methodology e.g. study design, sample size, number of cases and controls included, inclusion/exclusion criteria.
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Outcomes and prioritization Primary outcome:
The primary outcome will be grades obtained at the end of compulsory schooling i.e. GCSE level or equivalent examinations. In most cases we expect this to be a continuous measure assessing scores across a range of subjects. We anticipate there may be some cases where a binary measure is used, for example, pass/fail.
Secondary outcomes:
The secondary objectives may include school attendance and grades obtained at other stages on the educational trajectory if reported. Again, in most cases, we expect these to be continuous measures.
Missing data
For any questions about eligibility or data not obtained from the full paper review, the authors of the papers will be contacted if required. If after 6 weeks no clarification has been provided, the study will be included in the final analysis & discussion however will be identified as ideally requiring further information.
Assessment of risk of bias in included studies
The quality and risk of bias in the observational studies included in this review will be assessed using the Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in metaanalysis.(17) The Newcastle-Ottawa scale assesses cohort & case control studies based on three domains: 1) Selection of study groups 2) Comparability of study groups 3) Ascertainment of Exposure (Case-Control studies)/ Outcome (Cohort studies) Each study can be awarded a maximum of one star for each numbered component within the selection and exposure sections and a maximum of two stars can be given for the comparability section, creating a maximum of 9 stars per study. The higher the number of stars, the better quality the study and the lower the risk of bias. If any RCTs are identified for inclusion in this review, we will assess the quality and risk of bias using the Cochrane Risk of Bias Tool, as described in the Cochrane Handbook for Systematic Reviews of Interventions.(18) This tool assesses risk of bias using five main domains: selection bias, performance bias, reporting bias, detection bias and attrition bias. It allows categorisation of risk of bias using three main outcomes: High, Low or Unclear. In our review, this assessment will be completed by two independent reviewers (NO & RF). Any disagreements that cannot be resolved during moderation will be discussed with a third reviewer (JG).
Data synthesis
We will aim to conduct a meta-analysis using a random-effects model. The majority of the outcome data from included studies in our review is likely to be continuous, therefore the measure of effect will be analysed using standardised mean difference with 95% confidence interval. Any dichotomous outcome data will be analysed using risk ratios or odds ratios, which will also be converted to standardised mean difference with the appropriate transformations. In order to not lose information we will convert measures into a common metric and will aim to undertake sensitivity analyses to look for systematic difference according to transformations. We will use the statistical software Eppi-Reviewer 4.0(16) for our meta-analysis. If possible, a sensitivity analysis will be performed to explore the impact of decisions made during the calculation of effect sizes, the inclusion of different study designs, and the impact of risk of bias assessments. If we are unable to analyse data using meta-analysis, we will conduct a narrative synthesis. In this case, we will narratively summarise and tabulate the results found during data extraction in order to identify patterns in study design and outcomes across the included studies.
Assessment of heterogeneity
We will assess heterogeneity between the included studies by visual assessment of forest plots (for any minimal overlap) and use of statistical tests including the Chi 2 test and the I 2 statistic. If there is evidence of statistical heterogeneity, we will attempt to explore the reasons for the heterogeneity by using subgroup analyses based on the following:
• Patient demographics e.g. age, gender • Diabetes specific characteristics e.g. age at diagnosis, HbA1c We will also consider a random-effects meta-regression.
Publication-bias
We will examine funnel plots and conduct tests (Egger's test) to assess the potential for publication bias where there are sufficient (>10) studies.
Quality of overall body of evidence
We will assess the quality of evidence for all outcomes using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Risk of bias, directness, precision, heterogeneity and publication bias will be assessed and quality of the evidence will then be judged as high, moderate, low or very low. Results will be presented in 'Summary of findings' tables as recommended by the Cochrane Handbook for Systematic Reviews of Interventions.(18) 
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Introduction
Type 1 diabetes has the potential to significantly impact on children's educational attainment. With the increase in incidence, quantifying this effect would be useful to assess how much additional support should be focused on children with type 1 diabetes in school.
Methods and analysis
We will conduct a systematic review of all observational studies and randomised controlled trials including individuals both with and without a diagnosis of type 1 diabetes who have undertaken high stakes testing at the end of compulsory schooling when under 18 years of age. The search will cover both peer-reviewed and grey Study selection and data extraction will be performed independently by two reviewers with any disagreements resolved via a third reviewer. The quality and risk of bias in the observational studies included in this review will be assessed using the Newcastle-Ottawa Scale (NOS). We aim to conduct a meta-analysis and will assess heterogeneity between the included studies as well as potential for publication bias if sufficient (>10) studies are included.
Results and dissemination
Formal ethical approval is not required as individual patient data will not be collected. Results will be disseminated through peer-reviewed publication and conference presentations.
PROSPERO Registration number
CRD42017084078. • Our findings will be reported using the recommended methods and checklist of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Introduction
Background Type 1 diabetes (T1DM), also known as insulin-dependent or juvenile diabetes, is an autoimmune disease which causes destruction of the insulin-producing beta cells in the pancreas, preventing the body from adequately regulating blood glucose levels. It can occur at any age but is most commonly diagnosed in childhood and adolescence. (1) 
Rationale for Review
The health outcomes of type 1 diabetes in children are well documented, but the wider psychosocial impacts are less established and there is a lack of understanding of the effects on educational attainment.(5) These wider impacts are not only important in themselves, but also have the potential to have an effect on later life health outcomes through mechanisms such as employment, income and social status.
Many patients and their families express concerns about the potential negative impact that T1DM may have on a child's attendance at school,(6) and many report worries about schools' ability to support children with diabetes. (7) Hypoglycaemia, hyperglycaemia and diabetic ketoacidosis as well as psychological challenges and reduced attendance due to illness and hospital appointments are all factors which may result in poorer educational attainment for children with type 1 diabetes compared with their non-diabetic counterparts.(8-10) There is conflicting evidence as to the exact effect T1DM has on educational attainment and the real magnitude of this impact. (6) Previous literature has focused on the effects of type 1 diabetes on cognitive functioning in children.
In a meta-analysis in 2008, Gaudieri et al (9) found that paediatric type 1 diabetes was found to be associated with poorer performance in learning and memory skills as well as attention and executive function. They found that these lower cognitive scores were most pronounced with early-onset As implied both in theory and in law, type 1 diabetes has the potential to significantly impact on children's educational attainment. Therefore, assessing and analysing the current evidence to quantify this effect may be useful in assessing what and how much support and educational interventions should be focused on children with type 1 diabetes in school.
Objectives
The primary objective of this review is to assess and analyse the current literature available on whether type 1 diabetes has an impact on educational attainment in individuals undertaking high stakes standardised testing under 18 years of age at the end of compulsory schooling. The secondary objectives include assessing the effect of type 1 diabetes on school attendance and educational attainment at other stages on the educational trajectory if reported.
Methods
We have used the Cochrane Handbook for Systematic Reviews of Interventions (20) to structure our methodological approach and we will report our findings using the recommended methods and checklist of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). (21) This protocol was created using the Preferred Reporting Items for Systematic Review and MetaAnalysis Protocols (PRISMA-P) guidelines. (22) This protocol is registered with PROSPERO 
Eligibility criteria
Type of study:
Population:
Controls/Comparators:
No diagnosis of type 1 diabetes before undertaking high stakes testing at the end of compulsory schooling. We will include studies using controls which allow estimates of an interpretable effect size, for example matched controls or population controls. We will record the type of control in data extraction and consider the implications in the review.
Outcome measures:
The primary outcome will be grades obtained in high stakes testing at the end of compulsory schooling. Secondary outcomes may include school attendance and grades obtained at other stages on the educational trajectory if reported.
Time frame:
The 2015 NICE guidelines state that since 2004 there have been major changes in routine management of type 1 diabetes, aiming to achieve better glucose control to reduce long term complications associated with the condition.(24) We will therefore include studies published after the year 2004 in order to comprehensively evaluate the most up-to-date available peer-reviewed and grey literature. The effect on educational attainment associated specifically with these treatment changes from 2004 may only become apparent at a later stage and therefore only seen in more recent or future studies. As a result, while it is likely that many qualifying studies will use cohorts receiving treatment prior to this year, we will record this as part of our data extraction and consider this as part of the review comparison.
Setting:
Search methods for identification of studies
We will search the following databases from January 2004 to January 2018, and will consider only studies published using the English language.
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Selection of studies
To select studies for further assessment, they will be imported and organised into Eppi-Reviewer 4.0 (25) and duplicates will be removed. Two independent reviewers (NO & RF) will screen the titles and abstracts of every record retrieved from the searches using the predetermined inclusion criteria using Eppi-Reviewer 4.0. (25) Records identified as potentially eligible on the basis of title and abstract will then be screened on full text according to set inclusion criteria. If there is any doubt or disagreement regarding study selection, there will be further discussion and, if required, involvement of a third reviewer (JG) to reach a consensus. Rationale for exclusion of studies at this stage will be documented. The remaining included studies will then undergo data extraction using a standardised pro-forma. A PRISMA flow diagram will be used to demonstrate the number of included and excluded studies.
Data collection
All included studies will undergo data extraction by 2 independent reviewers (NO & RF), using a standardised pro-forma. The pro-forma will be pilot tested initially to ensure consistency. Data extracted from each study will include: -Details of study e.g. first author, date of publication, country/region where study undertaken. -Details of study methodology e.g. study design, sample size, number of cases and controls included, inclusion/exclusion criteria, data linkage. -Modelling strategy and covariates/confounders adjusted for e.g. age, gender, socioeconomic group, age at diagnosis, duration of diabetes. -Outcomes -as stated below. Again, any disagreements will be discussed and a third reviewer (JG) will be consulted if required.
Outcomes and prioritization Primary outcome:
The primary outcome will be grades obtained in high stakes testing at the end of compulsory schooling. In most cases we expect this to be a continuous measure assessing scores across a range of subjects. We anticipate there may be some cases where a binary measure is used, for example, achieving five GCSEs (grades A to C) is a commonly used benchmark in UK educational research.
Secondary outcomes:
The secondary objectives may include school attendance and grades obtained at other stages on the educational trajectory if reported. Again, in most cases, we expect these to be continuous measures. 
Missing data
Assessment of risk of bias in included studies
The quality and risk of bias in the observational studies included in this review will be assessed using the Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in metaanalysis. (26) The Newcastle-Ottawa scale assesses cohort & case control studies based on three domains: 1) Selection of study groups 2) Comparability of study groups 3) Ascertainment of Exposure (Case-Control studies)/ Outcome (Cohort studies) Each study can be awarded a maximum of one star for each numbered component within the selection and exposure sections and a maximum of two stars can be given for the comparability section, creating a maximum of 9 stars per study. The higher the number of stars, the better quality the study and the lower the risk of bias. If any RCTs are identified for inclusion in this review, we will assess the quality and risk of bias using the Cochrane Risk of Bias Tool, as described in the Cochrane Handbook for Systematic Reviews of Interventions. (27) This tool assesses risk of bias using five main domains: selection bias, performance bias, reporting bias, detection bias and attrition bias. It allows categorisation of risk of bias using three main outcomes: High, Low or Unclear. We will also specifically analyse the linkage methodology used in all papers included, highlighting areas of potential bias which may impact on the overall quality of the studies. In our review, this assessment will be completed by two independent reviewers (NO & RF). Any disagreements that cannot be resolved during moderation will be discussed with a third reviewer (JG).
Data synthesis
We will aim to conduct a meta-analysis using a random-effects model. The majority of the outcome data from included studies in our review is likely to be continuous, therefore the measure of effect will be analysed using standardised mean difference with 95% confidence interval. Any dichotomous outcome data will be analysed using risk ratios or odds ratios, which will also be converted to standardised mean difference with the appropriate transformations. In order to not lose information we will convert measures into a common metric and will aim to undertake sensitivity analyses to look for systematic difference according to transformations. We will use the statistical software Eppi-Reviewer 4.0(25) for our meta-analysis. If possible, a sensitivity analysis will be performed to explore the impact of decisions made during the calculation of effect sizes, the inclusion of different study designs, and the impact of risk of bias assessments. If we are unable to analyse data using meta-analysis, we will conduct a narrative synthesis. In this case, we will narratively summarise and tabulate the results found during data extraction in order to identify patterns in study design and outcomes across the included studies. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 evidence of statistical heterogeneity, we will attempt to explore the reasons for the heterogeneity by using subgroup analyses based on the following:
Assessment of heterogeneity
Publication-bias
Quality of overall body of evidence
We will assess the quality of evidence for all outcomes using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Risk of bias, directness, precision, heterogeneity and publication bias will be assessed and quality of the evidence will then be judged as high, moderate, low or very low. Results will be presented in 'Summary of findings' tables as recommended by the Cochrane Handbook for Systematic Reviews of Interventions. (27) 
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METHODS
Eligibility criteria
8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 o n l y Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
7, 8
Study records: Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 5, 6
Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) 5 Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 5 Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications
5
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale
5, 6
Risk of bias in individual studies 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 6, 7
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 5-7 15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I 2 , Kendall's τ) 6, 7
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 6, 7 15d If quantitative synthesis is not appropriate, describe the type of summary planned 6 Meta-bias(es)
16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)
7
Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 7
* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 
